NCI R25 Courses Skills Development Eligibility Guide
Updated 8 official sources
Quick Answer: PAR-23-276 no longer accepts applications. NCI expired it early on June 18, 2026 under NOT-CA-26-017 (opens in a new tab), along with its sister notices PAR-23-277 and PAR-23-278.
Full answer and how we checked it
NCI now sends course applications to the parent R25, PA-27-034 (opens in a new tab), which opened August 25, 2026, has its next due date on January 25, 2027, and expires May 26, 2029. The 7 fit checks below still apply: course model, cancer research skills fit, launch readiness, participant definition, evaluation plan, clinical trial not allowed status, and route fit.
Who this is for: Cancer center educators, training program leaders, course directors, research deans, oncology departments, education offices, and sponsored-research teams deciding whether an NCI R25 course route fits.
Data note: This guide uses NIH PAR-23-276 (opens in a new tab), NCI R25 funding pages (opens in a new tab), NCI R25 course examples (opens in a new tab), Grants.gov listing 350415 (opens in a new tab), and Grantsights award-data signals checked on June 2, 2026, rechecked against NIH notices and NIH RePORTER (opens in a new tab) on October 9, 2026.
In this guide
- October 2026 Status: PAR-23-276 Expired, PA-27-034 Replaces It
- What NCI Funded Under PAR-23-276
- 7 PAR-23-276 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What NCI Doesn't Tell You
- 6 Evidence Assets That Make This R25 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day R25 Readiness Plan
- 5 Readiness Signals to Check Before Drafting
- 5 Final Research Checks Before Submission
- Sources
Quick Facts
- Agency
- HHS
- Deadline on record
- Jan 7, 2027 (notice closed)
- Status
- Closed
Assistance Listing 93.398: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.398, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 2,179
- Avg Award (whole listing)
- $1,021,124
- Median Award (whole listing)
- $344,088
- Total Funding (FY2024, whole listing)
- $216.8M
- YoY Funding Trend
- +2%
Data last verified: May 22, 2026
According to NIH in PAR-23-276 (opens in a new tab), this R25 supports research educational activities that complement formal training programs and build a workforce for biomedical, behavioral, and clinical research needs. For NCI, the course must connect to cancer research.
The decision question is whether the project is a course for skills development, not a research study, not a conference, and not a curriculum-development project that will not be ready to operate.
Use this guide with the live NCI R25 Courses program record. Then compare NIH grants complete guide, what is a NOFO, NCI K99 Clinical Trial Required guide, NCI K99 Clinical Trial Not Allowed guide, NCI Cancer Center Support Grants P30 guide, and the Grantsights grant database.
October 2026 Status: PAR-23-276 Expired, PA-27-034 Replaces It
PAR-23-276 was scheduled to run through January 8, 2027, but NOT-CA-26-017 (opens in a new tab) expired it, PAR-23-277 (research experiences), and PAR-23-278 (curriculum or methods development) effective June 18, 2026. The September 25, 2026 date listed in PAR-23-276 never happened under that notice. NCI's R25 award page (opens in a new tab) now lists 3 parent NIH R25 notices for its cancer research education program, and courses fall under PA-27-034, "Courses, Curriculum & Methods."
| PA-27-034 fact | What the notice and NCI say |
|---|---|
| Open date | August 25, 2026 |
| Due dates | September 25, 2026 (passed); January 25, 2027; May 25, 2027; then the standard January, May, and September 25 cycle |
| Expiration | May 26, 2029 |
| NCI course budget | Up to $300,000 direct costs per year for up to 5 years |
| NCI curriculum or methods budget | Up to $150,000 direct costs per year for up to 2 years |
| Indirect costs | 8% of modified total direct costs |
| Clinical trials | Not allowed |
| Review for January 25, 2027 | July 2027 review, October 2027 council, December 2027 earliest start |
The course rules carried over in substance. NCI's page still says the course must be offered in each year R25 support is requested, and that a team needing year one for development should propose curriculum or methods development instead. PAR-23-276 also required all instructional activities to finish within a 12-month period. Because PA-27-034 is a trans-NIH parent notice, its general text says budgets typically run no more than $500,000 direct costs, but NCI's own page sets the lower $300,000 course ceiling, so plan to that number.
What NCI Funded Under PAR-23-276
About 20 distinct projects show up under PAR-23-276 in a NIH RePORTER (opens in a new tab) pull Grantsights ran on October 9, 2026 (30 project-year records in FY2025 and FY2026). Grantsights analysis of those records shows yearly direct costs from about $99,700 to $303,800, with most new awards between $180,000 and $304,000.
| Award | Organization | Course |
|---|---|---|
| R25CA298916 | Cold Spring Harbor Laboratory | Methods in Cancer Neuroscience |
| R25CA174664 | American Association for Cancer Research | Integrative Molecular Epidemiology Workshop (renewal, year 12) |
| R25CA306814 | University of Minnesota | Biomarker development for cancer prevention |
| R25CA314622 | City of Hope (Beckman Research Institute) | Clinical trials nursing education |
| R25CA302442 | Wake Forest University Health Sciences | Qualitative Training Institute for cancer research |
Three patterns stand out. Several awards are long-running renewals, which NCI allows for courses (the AACR workshop and the Dana-Farber supportive oncology methods workshop are both in year 11 or later). Many funded courses target clinicians and allied professionals, such as social workers, nurses, and palliative care teams, not only PhD scientists. And research methods courses, from qualitative methods to implementation science, appear as often as wet-lab techniques.
7 PAR-23-276 Eligibility Stop Checks
| Stop check | Strong R25 signal | Red flag |
|---|---|---|
| Course model | Course, workshop, or short course is central | Research project in disguise |
| Cancer fit | Skills support cancer research workforce | General education only |
| Timeline | Course can operate early | Development delays launch |
| Participants | Audience and selection are clear | Audience is vague |
| Evaluation | Learning outcomes and metrics are defined | Satisfaction survey only |
| Trial status | No clinical trial | Human intervention study |
| Route fit | R25 is better than T, K, R, or conference route | Wrong mechanism |
An R25 education idea can be useful while the mechanism fit is weak. The issue is usually that the project is not course-centered enough.
5 Source Facts Applicants Should Know
According to NIH in PAR-23-276 (opens in a new tab), the funding number is PAR-23-276, the mechanism is R25, clinical trials are not allowed, and courses for skills development are the supported activity. According to NCI's R25 award page (opens in a new tab), the program supports educational activities that build the cancer research workforce.
According to NCI's R25 course examples (opens in a new tab), funded courses include cancer research education programs across clinical, data, communication, supportive care, and other cancer-relevant areas. According to USAspending.gov (opens in a new tab) data, the connected assistance listing (93.398) had about $216.8M in FY2024 obligations across 2,179 awards active that year.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-23-276 |
| Mechanism | R25 research education |
| Clinical trial status | Not allowed |
| Program focus | Cancer research skills courses |
| Next standard date | None; the September 25, 2026 date was canceled when the notice expired |
| Budget cap | $300,000 direct costs per year |
| Expiration date | June 18, 2026, early under NOT-CA-26-017 (opens in a new tab) (originally January 8, 2027) |
What NCI Doesn't Tell You
Within 21 days, answer 4 practical questions. First, an R25 course is not a training grant. It can complement formal training, but it does not replace T32, K, or fellowship support.
Second, participants matter. For example, a center building a short course on cancer data science would need to define learner stage, selection, prerequisites, mentoring touchpoints, and skill assessment. PAR-23-276 also expected participants to come from a regional or national pool beyond the applicant institution.
Third, if course development would prevent launch in year one, NIH points applicants toward companion curriculum or methods development routes. Don't use the courses route for a course that is not ready to run.
Fourth, participant support rules are delicate. Individuals supported by K, T, or F mechanisms may receive educational experiences through an R25, but salary or stipend supplementation is restricted.
According to NCI, courses for skills development should provide evidence-based cancer research education derived from biomedical, behavioral, and clinical cancer research findings. According to NIH PAR-23-276 and NCI's current R25 page, if course development would prevent the course from running in year 1, the companion curriculum or methods development route may be better. If the project is mainly research, a conference, or an undeveloped course concept, skip this route before writing the budget.
6 Evidence Assets That Make This R25 Stronger
Within 21 days, build 6 evidence assets. Asset 1 is a course logic model. Include audience, skills, activities, faculty, products, and outcomes.
Asset 2 is a participant plan. Include eligibility, recruitment, selection, cohort size, accessibility, and expected research role.
Asset 3 is the curriculum map. Tie modules to cancer research skill gaps and learning outcomes.
Asset 4 is an evaluation plan. Include pre/post measures, product review, skill demonstration, follow-up, and career or research outputs.
Asset 5 is a faculty and operations plan. Courses fail when faculty roles, time, platform, and logistics are vague.
Asset 6 is the route comparison. Compare courses, curriculum development, T32, K, conference, and R01 routes.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PA-27-034 courses track | Course can run and build cancer research skills | Route fits; replaces PAR-23-276 |
| PA-27-034 curriculum or methods track | Curriculum or methods need development first | Replaces PAR-23-278; NCI caps it at $150,000 a year for 2 years |
| T32 or F/K | Formal trainee support is central | Training route may fit |
| R13 conference | Meeting is the product | Conference route may fit |
| R01 | Research question is central | Education route may be wrong |
The strongest R25 applications make the educational product and learner outcome obvious.
6 Bad-Fit Signals
First, the project is mainly research. Second, the course cannot operate in year one. Third, the audience is not defined.
Fourth, evaluation is weak. Fifth, the activity includes a clinical trial. Sixth, the work is a conference or formal degree program rather than a course for skills development.
Those stop checks help users avoid treating R25 as a flexible bucket for any education idea.
21-Day R25 Readiness Plan
Days 1 through 3 should confirm you're applying to PA-27-034, not the expired PAR-23-276, and check source status, deadline, clinical-trial-not-allowed status, audience, and course type. Days 4 through 7 should build the curriculum map.
Days 8 through 12 should write the participant plan and faculty plan. Days 13 through 16 should build evaluation and follow-up metrics. Days 17 through 21 should compare R25 courses, R25 curriculum, T, K, F, conference, and research routes.
5 Readiness Signals to Check Before Drafting
Within 21 days, check 5 readiness signals. Signal 1 is course fit: the core product should be a course, workshop, short course, or similar skills-development activity.
Signal 2 is launch fit: the course should be ready enough to operate early, not spend the full project period in development.
Signal 3 is participant fit: the audience, prerequisites, selection, cohort size, and expected research role should be explicit.
Signal 4 is evaluation fit: skill demonstration, work products, follow-up, and research outputs should matter more than satisfaction alone.
Signal 5 is budget fit: participant costs belong in the Participant/Trainee Support Costs section, PAR-23-276 capped course-related participant expenses at $500 and per diem at $300 per day, and it didn't allow costs for full-time participants supported for a continuous 12-month period. Check PA-27-034 for its current participant-cost rules before you price the course.
5 Final Research Checks Before Submission
Within 21 days, finish 5 final research checks. Check 1 is the course model. The applicant should be able to describe who attends, what they practice, what they produce, and how skills will be assessed. If the activity is mostly a conference, this isn't the right page to follow.
Check 2 is cancer research fit. A course about data, communication, supportive care, methods, or community work can fit only when the cancer research use is plain. The guide should keep pushing users to state which cancer research skill changes and why NCI is the right home.
Check 3 is launch readiness. Some course teams spend the whole project period building the product. PAR-23-276 is stronger when the course can operate early, learn from participants, and improve in later cycles.
Check 4 is participant support. Salary, stipends, trainee support, and educational experiences can create confusion. It's better to check this early than to design a budget around assumptions that do not hold.
Check 5 is the route memo. You're ready to draft only when the team can say why this is R25 courses, not R25 curriculum development, T32, K award, R13 conference, R01, or internal training funds. Write that route memo before anyone builds the budget.
Before each cycle, recheck PA-27-034 and the NCI R25 page for notices that change dates or budgets. NCI expired three education notices at once in June 2026 with no advance date, so an internal summary written earlier in the year may still point to PAR-23-276. If the learner group, course modules, faculty roles, evaluation plan, and cancer research use aren't clear yet, do a course-readiness rewrite before the budget is built.
Sources
- NIH PAR-23-276 (opens in a new tab) (expired)
- NOT-CA-26-017 early expiration notice (opens in a new tab)
- NIH PA-27-034 parent R25, Courses, Curriculum & Methods (opens in a new tab)
- NIH RePORTER (opens in a new tab) awards under PAR-23-276, pulled October 9, 2026
- NCI R25 award page (opens in a new tab)
- NCI R25 courses for skills development opportunities (opens in a new tab)
Largest awards active in FY2024
One row per recipient, its largest award | 2,179 Assistance Listing records | Avg: $1.0M
Baylor College of Medicine
TX
Regents of the University of California, San Francisco, the
CA
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the R25 record
Check PAR-23-276, September 2026 timing, course model, $300,000 cap, and no-trial status.
Review NIH mechanics
Use when the team needs standard due dates, education award, and budget setup context.
Compare cancer center support
Use when the course sits inside a broader cancer center training or education plan.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-23-276 fund?
It funded NCI R25 courses for skills development in cancer research. NCI expired it early on June 18, 2026 (NOT-CA-26-017). New NCI course applications now go through the parent R25, PA-27-034.
Are clinical trials allowed?
No. PAR-23-276 was clinical trial not allowed, and so is its replacement route, PA-27-034.
What kinds of activities fit?
Courses, workshops, short courses, and related research education activities that build skills for cancer research can fit.
What should applicants compare?
PAR-23-276 has expired, so compare the parent R25 course route (PA-27-034) with NCI R25 curriculum or methods development, training grants, conference routes, and standard research mechanisms.
Who should skip this route?
Skip it if the main product is research, a clinical trial, a conference, or curriculum development that cannot launch as a course in year one.
Last updated October 12, 2026. Corrected October 13, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-112 language development R01 eligibility Guide
PAR 25 112 language development guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
PAR-25-153 NCI Assay Screening R01 Eligibility Guide
NIH PAR-25-153 guide: NCI assay-development and screening R01 eligibility, clinical-trial-not-allowed fit, stages, and review checks.
PAR-25-444 CCSG P30 eligibility Guide
PAR-25-444 CCSG P30 guide: $6M or $10M funding-base rule, $1.2M to $1.5M caps, 2027 due dates, and FY2026 award data for 74 NCI cancer centers.
PAR-25-135 NCI K99 eligibility Guide
PAR 25 135 NCI K99 guide: 7 checks for eligibility, deadlines, budget, evidence, route fit, review criteria, and the 2027 K award changes.
NCI K99 Clinical Trial Required Guide
PAR-25-313 guide: NCI K99/R00 clinical trial required eligibility, postdoc limits, K99 to R00 transition, salary, and route checks.
NCI Payline 2026: No Cutoff, Budget Cuts, R01 Odds
NCI dropped paylines for FY2026 and cuts new R01 budgets by 6.5% to 17%. NIH tables show NCI funded 6.9% of new R01 applications in FY2025.